Participated · Seed · Jul 2026

Adjuvia Therapeutics, founded in 2023 and based in San Francisco, is developing oral therapeutics intended to repair mitochondrial damage by addressing oxidative stress, chronic inflammation, and organ degeneration. Its lead program, ATI-105, is a blood-brain barrier-penetrant lipid nanoparticle formulation of a novel astaxanthin molecule claimed to have superior bioactivity and bioavailability. In preclinical models of mitochondrial disease, ATI-105 demonstrated reductions in reactive oxygen species and chronic inflammation, evidence of cellular repair, improved organ function, and extended lifespan. The company plans to submit an IND for ATI-105 this summer, initiate a Phase 1 trial in healthy volunteers in Fall 2026, and begin a Phase 1/2 study in Friedreich’s ataxia patients in early 2027. The recent $8 million Series Seed financing led by JLO Ventures will fund these clinical development milestones.

Participated · Equity · Apr 2026

Osteoboost Health Inc. develops a wearable Class II prescription device worn around the hips that delivers low-magnitude vibration therapy to the lumbar spine and hips as a non-drug treatment for low bone density and osteopenia, particularly in postmenopausal women. The treatment approach is based on research originally funded by NASA and, in a double-blind trial at the University of Nebraska Medical Center, users who adhered to at least three 30-minute sessions per week for 12 months saw bone density loss reduced by 85% in the spine and 55% in the hips, per the company. The device received a Breakthrough Device designation in 2024 and was later cleared via the FDA De Novo pathway; the company began shipping in May. Since launch it has been prescribed by more than 2,500 physicians, including clinicians at over 30 academic medical centers. The company was also named to TIME’s 2025 list of Best Inventions. Osteoboost plans to use the new financing to scale manufacturing, expand clinical research, and broaden commercialization.

Participated · Equity · Mar 2026

Founded by Sandra Velasquez and launched in 2020, Nopalera describes itself as a modern Mexican lifestyle and beauty brand built for the "modern beauty explorer." Its product lineup includes signature fragrances, hair care, bath and body products, and candles. Nopalera sells through Ulta.com, Ulta Mexico, Ulta Middle East, Credo Beauty, Mecca, Amazon, hundreds of independent retailers nationwide, and its own website. The founder began the brand in 2019 while in New York City and has positioned the company around Latino cultural representation in beauty. The company recently raised $4 million in growth capital led by Morgan Stanley's Next Level Fund to accelerate retail expansion and product development. The new financing also added Morgan Stanley to Nopalera's board of directors.

Participated · Series H · Feb 2026

GrubMarket is an AI-driven technology and B2B e-commerce company that digitizes, automates, and streamlines the American and global food supply chain. Its offerings include enterprise SaaS such as an Inventory Management AI Agent and Reporting AI Agent, as well as a tech-enabled marketplace that serves customers in all 50 U.S. states and more than 70 countries. Recent acquisitions—Coast Citrus, Delta Fresh Produce, and Procurant—have expanded its reach; Procurant alone facilitates $5.5 billion in GMV for over 850 customers across 14 countries. The firm operates with what it calls a self-sustaining, profitable model and has been recognized on the CNBC Disruptor 50 list for three consecutive years. It runs the Sustainable California initiative, which promotes organic farming and has funded hundreds of thousands of tree plantings. Backed by a $4.5 billion pre-money valuation, the company plans to invest further in talent, financial infrastructure, technology development, and additional acquisitions to expand across North America, South America, Europe, and Africa.

Participated · Series B · Sep 2025

Mercy BioAnalytics develops extracellular vesicle–based liquid biopsy tests aimed at the early detection of cancer. Its patented Mercy Halo platform uses biomarker co-localization to interrogate abundant blood-based extracellular vesicles that carry cancer signatures from their cell of origin. The company’s initial focus is the early detection of ovarian and lung cancers, and its blood-based ovarian cancer test portfolio is designed to detect pre-clinical high grade serous ovarian carcinoma in post-menopausal women. Mercy says the Mercy Halo ovarian cancer screening test shows unprecedented sensitivity and specificity in a blinded evaluation of samples from a randomized controlled trial. The company plans to commercialize its ovarian cancer tests and expand the Mercy Halo portfolio to include multi-cancer and lung cancer screening tests. Mercy is based in Waltham, Mass., and recently closed a financing to support commercialization and portfolio expansion. Mercy BioAnalytics is advancing the Mercy Halo extracellular vesicle‑based liquid biopsy platform to enable early detection of cancer. Mercy Halo seeks high clinical sensitivity and specificity by simultaneously detecting multiple cancer‑related biomarkers co‑localized on individual tumor‑derived extracellular vesicles. The test can be run on a very small volume of serum or plasma and uses a simple PCR‑based readout. The company closed an oversubscribed $41 million Series A to advance development and commercialization, with an initial focus on high‑risk lung cancer screening. Proceeds will also support clinical programs in ovarian cancer and the development of a broader portfolio of early‑detection tests. Preliminary data presented at ASCO, AACR and EDCC demonstrated promising performance for detecting Stage I and II lung and ovarian cancers, and Mercy is planning larger independent validation studies.